pembrolizumab,toripalimab,nivolumab,ipilimumab,Atezolizumab,durvalumab,carboplatin,gemcitabine,paclitaxel,vinorelbine,cisplatin,docetaxel,pemetrexed
merck,Roche,BMS,Coherus,Junshi Biosciences,Astrazeneca
['lcsm,(-blcsm)']
important to consider, what happens to the 15-20% of patients on these trials who do not make it to surgery? #lcsm #asco23 
Thoracic Medical Oncologist, Assistant Professor @MDAndersonNews | Interested in patient education, PROs, personalized care | 🫁#cancer #lcsm | Views are my own